Skip to main content
Top
Published in: Archives of Osteoporosis 1/2015

01-12-2015 | Case Report

Risedronate as an intra-abdominal sepsis mimic: a case report

Authors: Sonali Shah, Cameron Jeremiah, Douglas Johnson, Scott Baker

Published in: Archives of Osteoporosis | Issue 1/2015

Login to get access

Abstract

Summary

This case report highlights the potential severity of bisphosphonate-associated reactions.

Case report

A 76-year-old lady underwent several hospital admissions for investigation of fever associated with rigors, abdominal pain, and vomiting.

Discussion

Despite multiple investigations, no cause was found, but the timing of the symptoms coincided with monthly risedronate administration.
Literature
1.
go back to reference Royal Australian College of General Practitioners (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older women Royal Australian College of General Practitioners (2010) Clinical guideline for the prevention and treatment of osteoporosis in postmenopausal women and older women
2.
go back to reference Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11(1):83–91PubMedCrossRef Reginster J-Y, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11(1):83–91PubMedCrossRef
4.
go back to reference Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen. Bone 59:44–52. doi:10.1016/j.bone.2013.10.017 PubMedCrossRef Hagino H, Kishimoto H, Ohishi H, Horii S, Nakamura T (2014) Efficacy, tolerability and safety of once-monthly administration of 75 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5 mg once-daily dosage regimen. Bone 59:44–52. doi:10.​1016/​j.​bone.​2013.​10.​017 PubMedCrossRef
5.
go back to reference McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou C-L, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P (2013) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int 24(1):293–299PubMedPubMedCentralCrossRef McClung MR, Zanchetta JR, Racewicz A, Roux C, Benhamou C-L, Man Z, Eusebio RA, Beary JF, Burgio DE, Matzkin E, Boonen S, Delmas P (2013) Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int 24(1):293–299PubMedPubMedCentralCrossRef
Metadata
Title
Risedronate as an intra-abdominal sepsis mimic: a case report
Authors
Sonali Shah
Cameron Jeremiah
Douglas Johnson
Scott Baker
Publication date
01-12-2015
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2015
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-015-0213-8

Other articles of this Issue 1/2015

Archives of Osteoporosis 1/2015 Go to the issue